Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CS1

Small molecule

Phase 2 Most advanced trial
3 Registered trials

What is CS1?

CS1 is a delayed-release capsule formulation containing 160 mg sodium valproate per capsule, administered orally in divided or once-daily doses. It is being studied in pulmonary arterial hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Respiratory
In trials of
ABT, CERENO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07761572 Phase 2 Pulmonary Arterial Hypertension Not yet recruiting CERENO
NCT05224531 Phase 2 Pulmonary Arterial Hypertension Completed CERENO
NCT06321705 N/A Pulmonary Arterial Hypertension No longer available ABT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Arterial Hypertension

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.